Novartis Files 2025 Annual and Nonfinancial Reports with U.S. SEC

Novartis ( (NVS) ) just unveiled an announcement.

On February 4, 2026, Novartis AG, acting as a foreign private issuer under the U.S. Securities Exchange Act of 1934, filed a Form 6-K with the U.S. Securities and Exchange Commission to furnish its Annual Report 2025 and its Report on Nonfinancial Matters 2025 as exhibits. The filing formally places the company’s 2025 financial and non-financial disclosures into the U.S. public record, reinforcing its ongoing compliance with U.S. reporting requirements and providing investors and other stakeholders with updated transparency on its performance and sustainability-related matters for the 2025 financial year.

The most recent analyst rating on (NVS) stock is a Buy with a $171.00 price target. To see the full list of analyst forecasts on Novartis stock, see the NVS Stock Forecast page.

Spark’s Take on NVS Stock

According to Spark, TipRanks’ AI Analyst, NVS is a Outperform.

Novartis presents a strong investment case with robust financial performance and positive earnings call highlights. The technical analysis supports a positive trend, though valuation metrics are moderate. The company’s strategic focus on innovation and expansion, despite some market challenges, underpins its growth potential.

To see Spark’s full report on NVS stock, click here.

More about Novartis

Novartis AG is a Switzerland-based global pharmaceutical company headquartered in Basel, focused on researching, developing and commercializing innovative medicines across multiple therapeutic areas. As a major player in the healthcare industry, it serves worldwide markets through prescription drugs and related healthcare products, with a strong emphasis on regulated public-market disclosure as a foreign private issuer in the United States.

Average Trading Volume: 1,667,903

Technical Sentiment Signal: Buy

Current Market Cap: $287.7B

See more data about NVS stock on TipRanks’ Stock Analysis page.